?Metoclopramide HCl?
??? D2/5-HT3 Antagonist | ?? Antiemetic for GERD & Gastroparesis | ?? >99% Purity?

?Overview?

Metoclopramide HCl is a dual-action antagonist targeting ?dopamine D2? and ?serotonin 5-HT3 receptors?, accelerating gastric motility and alleviating nausea/vomiting in ?GERD? and ?gastroparesis??12. With >99% purity, it meets pharmaceutical-grade standards for clinical use?23.

?Key Features?

• ?? Rapid Relief?

  : Symptomatic improvement within ?30–60 minutes?.

• ??? Dual Mechanism?

  : Blocks both D2 (gastric motility) and 5-HT3 (antiemetic) pathways?16.

• ??? High Compatibility?

  : Adaptable for oral tablets, IV injections, and IM formulations?2.

?Applications?

• ?GERD?

  : Reduces acid reflux and esophageal damage?16.

• ?Diabetic Gastroparesis?

  : Enhances delayed gastric emptying?6.

• ?Chemotherapy Support?

  : FDA-approved for oncology-related nausea?2.

?Quality Assurance?

• Complies with ?USP/EP? standards?.

• ?HPLC-verified purity (>99%)? and ?GC/MS-tested solvents?.

?Market Insight?

Global GI drug demand grows at ?6.2% CAGR (2025–2030)??5, driven by rising GERD cases (~20% adults in developed regions)?1. Metoclopramide remains a cost-effective frontline therapy?25.

?Keywords?: D2 antagonist, 5-HT3 blocker, antiemetic drug, GERD treatment, high-purity API

Citations: ?12 | Updated: Feb 2025